Skip to main navigation Skip to search Skip to main content

Solving patients with rare diseases through programmatic reanalysis of genome-phenome data

Solve-RD SNV-indel working group, Solve-RD DITF-GENTURIS, Solve-RD DITF-ITHACA, Solve-RD DITF-euroNMD, Solve-RD-DITF-RND, the Solve-RD Consortia, Leslie Matalonga, Carles Hernández, Davide Piscia, Enzo Cohen, Isabel Cuesta, Daniel Danis, Anne Sophie Denommé-Pichon, Yannis Duffourd, Christian Gilissen, Mridul Johari, Steven Laurie, Shuang Li, Leslie Matalonga, Isabelle NelsonSophia Peters, Ida Paramonov, Sivakumar Prasanth, Peter Robinson, Karolis Sablauskas, Marco Savarese, Wouter Steyaert, Joeri K. van der Velde, Antonio Vitobello, Rebecca Schüle, Matthis Synofzik, Ana Töpf, Lisenka Vissers, Richarda M. de Voer, Stefan Aretz, Gabriel Capella, Richarda M. de Voer, Gareth Evans, Jose Garcia Pelaez, Elke Holinski-Feder, Nicoline Hoogerbrugge, Andreas Laner, Carla Oliveira, Andreas Rump, Evelin Schröck, Anna Katharina Sommer, Verena Steinke-Lange, Iris te Paske, Marc Tischkowitz, Laura Valle, Alexander Münchau, Alexander Münchau, Katja Lohmann, Rebecca Herzog, Martje Pauly

Abstract

Reanalysis of inconclusive exome/genome sequencing data increases the diagnosis yield of patients with rare diseases. However, the cost and efforts required for reanalysis prevent its routine implementation in research and clinical environments. The Solve-RD project aims to reveal the molecular causes underlying undiagnosed rare diseases. One of the goals is to implement innovative approaches to reanalyse the exomes and genomes from thousands of well-studied undiagnosed cases. The raw genomic data is submitted to Solve-RD through the RD-Connect Genome-Phenome Analysis Platform (GPAP) together with standardised phenotypic and pedigree data. We have developed a programmatic workflow to reanalyse genome-phenome data. It uses the RD-Connect GPAP’s Application Programming Interface (API) and relies on the big-data technologies upon which the system is built. We have applied the workflow to prioritise rare known pathogenic variants from 4411 undiagnosed cases. The queries returned an average of 1.45 variants per case, which first were evaluated in bulk by a panel of disease experts and afterwards specifically by the submitter of each case. A total of 120 index cases (21.2% of prioritised cases, 2.7% of all exome/genome-negative samples) have already been solved, with others being under investigation. The implementation of solutions as the one described here provide the technical framework to enable periodic case-level data re-evaluation in clinical settings, as recommended by the American College of Medical Genetics.

Original languageEnglish
JournalEuropean Journal of Human Genetics
Volume29
Issue number9
Pages (from-to)1337-1347
Number of pages11
ISSN1018-4813
DOIs
Publication statusPublished - 01.09.2021

Funding

FundersFunder number
Ministerio de Economía y Competitividad
European Commission
Instituto de Salud Carlos IIIPT17/0009/0019, PT13/0001/0044
European Molecular Biology Laboratory
Horizon 2020 Framework Programme825575, 779257, 305444
Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España
European Regional Development Fund
Medical Research CouncilMR/S002065/1
EJP-RDH2020 779257, H2020 825575, FP7 305444

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Research Areas and Centers

    • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)
    • Centers: Center for Rare Diseases (ZSE)
    • Research Area: Medical Genetics

    DFG Research Classification Scheme

    • 2.23-07 Clinical Neurology, Neurosurgery and Neuroradiology
    • 2.23-06 Molecular and Cellular Neurology and Neuropathology

    Fingerprint

    Dive into the research topics of 'Solving patients with rare diseases through programmatic reanalysis of genome-phenome data'. Together they form a unique fingerprint.

    Cite this